<DOC>
	<DOC>NCT01263899</DOC>
	<brief_summary>This is a Phase 2 study to assess the efficacy of SB1518 in the treatment of patients with advanced lymphoid malignancies including Hodgkin Lymphoma, Mantle Cell Lymphoma and Indolent Lymphoma (follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma).</brief_summary>
	<brief_title>A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<criteria>Patients with histologically documented diagnosis of one of the following lymphoid malignancies: Hodgkin Lymphoma; Mantle Cell Lymphoma; Indolent Lymphoma (including follicular lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma); Patients must have received at least one prior treatment regimen; patients with Hodgkin Lymphoma must have received an autologous stem cell transplant, refused or been deemed ineligible for stem cell transplant; Able to understand and willing to sign the informed consent form. Any histology other than Hodgkin Lymphoma, Mantle Cell Lymphoma or Indolent Lymphoma; History of or active Central Nervous System (CNS) malignancy; Active graftversushost disease (GVHD);</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Lymphoid malignancies</keyword>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Indolent Lymphoma</keyword>
	<keyword>SB1518</keyword>
</DOC>